60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
DENVER - DaVita Inc. (NYSE:DVA) reported third-quarter earnings that fell short of analyst expectations, though the company maintained its full-year guidance. Shares edged down 0.2% following the announcement Wednesday.
The kidney care provider posted adjusted earnings of $2.51 per share for the quarter ended September 30, significantly below the analyst consensus of $3.23. Revenue came in at $3.42 billion, slightly missing estimates of $3.44 billion.
Despite the earnings miss, DaVita reaffirmed its full-year adjusted earnings guidance of $10.35 to $11.15 per share, which aligns with the analyst consensus of $10.80.
"Our third quarter performance was in line with our expectations and keeps us on track to achieve our full-year guidance," said Javier Rodriguez, CEO of DaVita. "Our consistent focus on providing outstanding care is the key to these results, enabling us to continuously invest in improving the lives of our patients and supporting our dedicated teammates and physician partners."
The company’s U.S. dialysis treatments totaled 7.24 million for the quarter, representing a 0.5% decrease compared to the second quarter. Year-over-year normalized non-acquired treatment growth declined 0.6%.
DaVita generated strong cash flow during the quarter, with operating cash flow of $842 million and free cash flow of $604 million. The company continued its share repurchase program, buying back 3.3 million shares at an average price of $140.67 per share.
During the quarter, DaVita incurred approximately $11.7 million in general and administrative charges related to a cybersecurity incident that occurred in the second quarter of 2025.
As of September 30, DaVita provided dialysis services to approximately 293,200 patients at 3,247 outpatient centers globally, with 2,662 centers in the United States and 585 centers across 14 other countries.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.